Clinical Trials Logo
  1. Home
  2. Type1 Diabetes
  3. NCT03236558

The Role of the Thymus in Type I Diabetes. — TregDiab  

Type1 Diabetes Clinical Trial

Official title:
Thymic Generation of Regulatory T Lymphocytes in Type I Diabetes Patients.

Clinical Trial Summary

Regulatory T lymphocytes play a major role in the protection from autoimmune pathology. Defects in immunosuppression mediated by these cells is therefore suspected to contribute to these diseases. This issue has very little been studied in humans.Regulatory T cells emigrated from the thymus will be isolated from the blood of patients and healthy controls. The repertoire of antigen-receptors will be analysed by high throughput sequencing and its diversity estimated using appropriate statistical models borrowed from ecology.

Clinical Trial Description

In the thymus of an animal model of type I diabetes, the population of regulatory T cells expresses a repertoire of antigen receptors that is approximately ten-fold less diverse than that found in mice resistant to autoimmune pathology. Genetic models later showed that this reduced diversity was involved in the susceptibility to diabetes. Researchers study the diversity of the TCR expressed by regulatory T cells from paediatric type I diabetes patients and controls. Regulatory T cells emigrated from the thymus will be isolated from the blood of patients and healthy controls. The repertoire of antigen-receptors will be analysed by high throughput sequencing and its diversity estimated using appropriate statistical models borrowed from ecology. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03236558
Study type Interventional
Source University Hospital, Toulouse
Contact
Status Withdrawn
Phase N/A
Start date March 2018
Completion date March 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05536232 - Residual Insulin Secretion in Patients With Type 1 Diabetes Under a Low Carbohydrate Diet or a Ketogenic Diet N/A
Completed NCT04255381 - Yale-Harvard Hotel-based Closed-Loop Studies in Children (HY-GRAID) N/A
Completed NCT04625595 - Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes Phase 1
Active, not recruiting NCT06177691 - Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study
Completed NCT04002557 - Optimising Consultation Summaries to Promote Good Health
Completed NCT05876273 - Neural-net Artificial Pancreas (NAP) N/A
Completed NCT03179280 - Effect of Dual-wave Insulin Bolus on Postprandial Glycaemia N/A
Recruiting NCT06253351 - Real-world Use of Hybrid Closed Loop in Adolescents and Young Adults 15-25 Years of Age With Type 1 Diabetes
Completed NCT01357603 - Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM Phase 1
Completed NCT04233034 - Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes Phase 3
Active, not recruiting NCT03782636 - Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD) Phase 2
Completed NCT04520971 - Closed-loop Insulin Delivery in Pregnant Women With Type 1 Diabetes N/A
Recruiting NCT05766657 - Evaluation of an Anti-inflammatory Diet in Autoimmune and Metabolic Diseases N/A
Completed NCT01838083 - Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus Phase 1